Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anastrozole + fulvestrant + gefitinib
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination therapy consisting of anastrozole (an aromatase inhibitor), fulvestrant (a selective estrogen receptor degrader), and gefitinib (an EGFR tyrosine kinase inhibitor). This triple combination targets both estrogen receptor signaling pathways and EGFR signaling to potentially overcome endocrine resistance in hormone receptor-positive breast cancer.
- Brand names
- Iressa + Arimidex + Faslodex
- Other names
- AFG (anastrozole, fulvestrant, and gefitinib combination)
02
Targets
Beyond the preview
Go deeper on anastrozole + fulvestrant + gefitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anastrozole + fulvestrant + gefitinib.